文献速递淋巴瘤

AKT抑制剂capivasertib与BCL-2抑制剂维奈克拉在弥漫大B细胞淋巴瘤中的强效联合获益

Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma.
PubMed 文献 · Leukemia · 2024-09-16

本文在DLBCL细胞系中开展体外联合药物筛选,发现AKT抑制剂capivasertib与BCL-2抑制剂维奈克拉联用可快速诱导caspase与PARP切割,并在细胞系及患者来源异种移植淋巴瘤模型中持久抑制肿瘤生长;在RCHOP难治性DLBCL体内模型中加用利妥昔单抗进一步延长缓解持续时间。

要点

  • capivasertib联合维奈克拉在DLBCL临床前模型中产生显著治疗获益并持久抑制肿瘤生长。
  • 在GCB-DLBCL的PTEN野生型、PTEN突变或PTEN蛋白降低细胞系中,两药快速诱导caspase与PARP切割。
  • 在RCHOP难治性DLBCL体内模型中加用利妥昔单抗进一步加深缓解的持久性。

核心结论

  • AKT抑制剂capivasertib与BCL-2抑制剂维奈克拉联合,并辅以抗CD20抗体,为DLBCL治疗提供了合理的临床前依据。

研究设计与样本

  • 在DLBCL细胞系 panel 中开展体外联合药物筛选,并在DLBCL细胞系及患者来源异种移植淋巴瘤模型中进行验证。

主要发现

  • capivasertib与维奈克拉在DLBCL临床前模型中产生显著治疗获益,并持久抑制肿瘤生长。
  • capivasertib与维奈克拉在GCB-DLBCL的PTEN野生型细胞系以及携带PTEN突变或PTEN蛋白降低的细胞系中快速诱导caspase与PARP切割。
  • 在RCHOP难治性DLBCL体内模型中加用利妥昔单抗进一步加深了capivasertib与维奈克拉缓解的持久性。

临床怎么用

  • 作者认为,上述结果支持将capivasertib与维奈克拉分别作为AKT与BCL-2抑制剂,联合抗CD20抗体用于DLBCL患者的治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The therapeutic potential of targeting PI3K/AKT/PTEN signalling in B-cell malignancies remains attractive. Whilst PI3K-α/δ inhibitors demonstrate clinical benefit in certain B-cell lymphomas, PI3K signalling inhibitors have been inadequate in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in part, due to treatment related toxicities. Clinically, AKT inhibitors exhibit a differentiated tolerability profile offering an alternative approach for treating patients with B-cell malignancies. To explore how AKT inhibition complements other potential therapeutics in the treatment of DLBCL patients, an in vitro combination screen was conducted across a panel of DLCBL cell lines. The AKT inhibitor, capivasertib, in combination with the BCL-2 inhibitor, venetoclax, produced notable therapeutic benefit in preclinical models of DLBCL. Capivasertib and venetoclax rapidly induced caspase and PARP cleavage in GCB-DLBCL PTEN wildtype cell lines and those harbouring PTEN mutations or reduced PTEN protein, driving prolonged tumour growth inhibition in DLBCL cell line and patient derived xenograft lymphoma models. The addition of the rituximab further deepened the durability of capivasertib and venetoclax responses in a RCHOP refractory DLBCL in vivo models. These findings provide preclinical evidence for the rational treatment combination of AKT and BCL-2 inhibitors using capivasertib and venetoclax respectively alongside anti-CD20 antibody supplementation for treatment of patients with DLBCL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Willis BS, Mongeon K, Dry H, et al. Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma. Leukemia. 2024. PMID: 39284898. doi:10.1038/s41375-024-02401-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。